caa a22 4500 467944008 CHVBK 20180405193735.0 cr unu---uuuuu 170328e20040101xx s 000 0 eng 10.1007/BF02665356 doi (NATIONALLICENCE)springer-10.1007/BF02665356 (NATIONALLICENCE)springer-10.1007/s00280-003-0690-0 Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study [Elektronische Daten] [Serafín Morales, Antonio Lorenzo, Manuel Ramos, Pedro Ballesteros, Miguel Méndez, Concepción Almanza, Javier Castellanos, José Moreno-Nogueira, Joaquín Casal, José Lizón, Amparo Oltra, Adolfo Frau, Ignacio Machengs, Antonio Galán, Joaquín Belón, Cristina Llorca] Purpose: In this multicentre phase II study, the efficacy and safety profile of the combination of docetaxel and epirubicin as first-line chemotherapy for metastatic breast cancer (MBC) were evaluated.Methods: Epirubicin (75 mg/m2) and docetaxel (75 mg/m2) were given intravenously once every 3 weeks for six cycles to 133 patients with MBC.Results: The overall clinical response rate was 67% (complete and partial responses were 23% and 44%, respectively). The median time to progression was 10.8 months (95% CI 9.7-12.6) and the median overall survival was 19.5 months. Granulocyte colony-stimulating factor support was administered to 32% of patients and in 22% of cycles. Grade 3/4 neutropenia occurred in 35% of patients and febrile neutropenia in 19%. The most frequent grade 3/4 nonhaematological toxicities (as percent of patients) were asthenia (6%), vomiting (5%) and nausea (5%). No patients developed congestive heart failure.Conclusions: The combination of docetaxed and epirubicin was highly active as first-line treatment for MBC and showed a manageable toxicity profile. Springer-Verlag, 2003 Docetaxel nationallicence Epirubicin nationallicence Metastatic breast cancer nationallicence First-line chemotherapy nationallicence Morales Serafín Medical Oncology Service, Hospital Arnau de Vilanova, Avda. Alcalde Rovira Roure, 80, 25198, Lleida, Spain aut Lorenzo Antonio Hospital Puerto Real, Cádiz, Spain aut Ramos Manuel Centro Oncológico de Galicia, A Coruña, Spain aut Ballesteros Pedro Hospital La Inmaculada, Almería, Spain aut Méndez Miguel Hospital de Móstoles, Madrid, Spain aut Almanza Concepción Clínica Povisa, Vigo, Spain aut Castellanos Javier Complejo Hospitalario Xeral Cíes, Vigo, Spain aut Moreno-Nogueira José Hospital Virgen del Rocío, Sevilla, Spain aut Casal Joaquín Hospital Do Meixoeiro, Vigo, Spain aut Lizón José Hospital San Juan de Alicante, Alicante, Spain aut Oltra Amparo Hospital Virgen de los Lirios, Alicante, Spain aut Frau Adolfo Hospital Provincial de Castellón, Castellón de la Plana, Spain aut Machengs Ignacio Hospital Sagrado Corazón-La Alianza, Barcelona, Spain aut Galán Antonio Hospital de Sagunto, Valencia, Spain aut Belón Joaquín Hospital Virgen de las Nieves, Granada, Spain aut Llorca Cristina Hospital General de Elda, Alicante, Spain aut Cancer Chemotherapy and Pharmacology Springer-Verlag 53/1(2004-01-01), 75-81 0344-5704 53:1<75 2004 53 280 https://doi.org/10.1007/BF02665356 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02665356 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Morales Serafín Medical Oncology Service, Hospital Arnau de Vilanova, Avda. Alcalde Rovira Roure, 80, 25198, Lleida, Spain aut NATIONALLICENCE 700 1- Lorenzo Antonio Hospital Puerto Real, Cádiz, Spain aut NATIONALLICENCE 700 1- Ramos Manuel Centro Oncológico de Galicia, A Coruña, Spain aut NATIONALLICENCE 700 1- Ballesteros Pedro Hospital La Inmaculada, Almería, Spain aut NATIONALLICENCE 700 1- Méndez Miguel Hospital de Móstoles, Madrid, Spain aut NATIONALLICENCE 700 1- Almanza Concepción Clínica Povisa, Vigo, Spain aut NATIONALLICENCE 700 1- Castellanos Javier Complejo Hospitalario Xeral Cíes, Vigo, Spain aut NATIONALLICENCE 700 1- Moreno-Nogueira José Hospital Virgen del Rocío, Sevilla, Spain aut NATIONALLICENCE 700 1- Casal Joaquín Hospital Do Meixoeiro, Vigo, Spain aut NATIONALLICENCE 700 1- Lizón José Hospital San Juan de Alicante, Alicante, Spain aut NATIONALLICENCE 700 1- Oltra Amparo Hospital Virgen de los Lirios, Alicante, Spain aut NATIONALLICENCE 700 1- Frau Adolfo Hospital Provincial de Castellón, Castellón de la Plana, Spain aut NATIONALLICENCE 700 1- Machengs Ignacio Hospital Sagrado Corazón-La Alianza, Barcelona, Spain aut NATIONALLICENCE 700 1- Galán Antonio Hospital de Sagunto, Valencia, Spain aut NATIONALLICENCE 700 1- Belón Joaquín Hospital Virgen de las Nieves, Granada, Spain aut NATIONALLICENCE 700 1- Llorca Cristina Hospital General de Elda, Alicante, Spain aut NATIONALLICENCE 773 0- Cancer Chemotherapy and Pharmacology Springer-Verlag 53/1(2004-01-01), 75-81 0344-5704 53:1<75 2004 53 280 NATIONALLICENCE 856 40 https://doi.org/10.1007/s00280-003-0690-0 text/html Onlinezugriff via DOI Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE NATIONALLICENCE NL-springer